Tag Archives: Supreme Court

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, Strategy, pricing | Also tagged , , , , , , , | 6 Comments

The FTC's Beef with Pay For Delay: What's the Fuss?

Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive on the grounds that these settlements amount to a restraint of trade under the commerce clause of the [...]
Posted in IP, Legal, Market Access, Regulatory | Also tagged , , , | 1 Comment

The Yin and Yang of the Court Decision on HCR

by Tom Norton If you’re like me, you probably bounded out of bed on Thursday morning, took in all the news you could find about the Supreme Court and healthcare reform…and then you waited.  You waited patiently for the biggest legal call in American healthcare history.  And then, there it was. What did we learn?  Well, first, [...]
Posted in FDA, Legal, Market Access, Regulatory, Strategy, healthcare, leadership | Also tagged , , , | 1 Comment

HCR and the Supreme Court: Three Important Days in March

The Supreme Court will open up deliberations on the constitutionality of three important parts of healthcare reform (HCR) this month. by Tom Norton After nearly two years of legal wrangling, on November 14, 2011 the Supreme Court (SCOTUS) determined that as a result of contradictory US Appellate Courts findings on the Patient Protection and Affordable Care Act, [...]
Posted in Legal, Strategy, healthcare | Also tagged , , , | Leave a comment

Supreme Court Strikes down Vermont Law, Upholds Rep Free Speech

June 23rd was a good day for the pharmaceutical industry. The Supreme Court released two decisions that largely went pharma’s way. There was much rejoicing across the industry, and for good reason, business as usual won out. In PLIVA v. Mensing, the Court ruled that generic drug companies should comply with federal regulations instead of [...]
Posted in Legal | Also tagged , , | Leave a comment